Advanced in Chromosome 8p Deletion

Frederic Baron

Liege, WAL, BE 
Advanced in Chromosome 8p Deletion
Liege, WAL, BE 
OverviewLocationsClinical Research

Overview

Frederic Baron practices in Liege, Belgium. Mr. Baron is rated as an Advanced expert by MediFind in the treatment of Chromosome 8p Deletion. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 198 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chromosome 8p Deletion.

Gender
Male

Locations

Liege, WAL, Belgium
Other Locations
Belgium
Sart Tilman, WAL 4000, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donors After Reduced-intensity Conditioning: a Phase II Randomized Study Comparing 2 GVHD Prophylaxis Regimens
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donors After Reduced-intensity Conditioning: a Phase II Randomized Study Comparing 2 GVHD Prophylaxis Regimens
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2024
Intervention Type: Drug
Study Drugs: Mycophenolate Mofetil, Sirolimus
Study Phase: Phase 2
Donor Regulatory T Cells (Treg) Infusion (DTI) in Patients With Steroid-refractory Chronic Graft-versus-host Disease (GVHD)
Donor Regulatory T Cells (Treg) Infusion (DTI) in Patients With Steroid-refractory Chronic Graft-versus-host Disease (GVHD)
Enrollment Status: Terminated
Publish Date: September 22, 2022
Intervention Type: Drug, Other
Study Drug: Rapamycin
Study Phase: Phase 2
Infusion of Third-party Mesenchymal Stem Cells After Renal or Liver Transplantation. A Phase I-II, Open-label, Clinical Study
Infusion of Third-party Mesenchymal Stem Cells After Renal or Liver Transplantation. A Phase I-II, Open-label, Clinical Study
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
Enrollment Status: Terminated
Publish Date: September 08, 2021
Intervention Type: Other, Biological
Study Drug: Mesenchymal Stem Cells
Study Phase: Phase 2
View 3 Less Clinical Trials

198 Total Publications

EEG characteristics of central nervous system graft-versus-host disease.
EEG characteristics of central nervous system graft-versus-host disease.
Journal: Journal of neurophysiology
Published: May 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Baron's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile